EHA 2021 | The DREAMM-5 PLATFORM trial
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the ongoing DREAMM-5 trial (NCT04126200), a Phase I/II study designed to identify effective belantamab mafodotin combinations for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Belantamab mafodotin is an antibody-drug conjugate containing humanized monoclonal antibodies against the B-cell maturation antigen, and promising results are expected with its use. Dr Richardson outlines the agents being investigated for combination, such as the monoclonal antibody isatuximab, the anti-inducible T-cell co-stimulator (ICOS) receptor agonist antibody feladilimab, and the gamma secretase inhibitor nirogacestat. The dose-exploration (DE) phase will determine the recommended Phase II dose and the cohort expansion (CE) phase will identify the overall response rate, along with safety and tolerability for each combination treatment. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Paul Richardson, MD, has received institutional research support from Oncopeptides, Celgene/BMS, Takeda, and Karyopharm. He has received honoraria for his role as an Advisory Committee member from Karyopharm, Oncopeptides, Celgene/BMS, Takeda, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca, and Protocol Intelligence.
